New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis

Renal cell carcinoma (RCC) accounts for approximately 400 000 diagnoses and 175 000 deaths each year[1]. Overall, 50%-60% of the patients require systemic treatments for metastatic disease (mRCC)[2].

Source: Cancer Treatment Reviews - March 16, 2022 Category: Cancer & Oncology Authors: Pasquale Lombardi, Marco Filetti, Rosa Falcone, Rossella Di Bidino, Roberto Iacovelli, Chiara Ciccarese, Emilio Bria, Giampaolo Tortora, Giovanni Scambia, Gennaro Daniele Tags: Systematic or Meta-analysis Studies Source Type: research